drugset / Trial / NCT06400537
Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus
Phase 1
Recruiting
25 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
ITabMed Co., Ltd. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to explore the safety and efficacy of recombinant CD19xCD3 double antibody (A-319) in active/refractory systemic lupus erythematosus (SLE).
Timeline
- Start
- 2024-07-20
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | A-319 | Monoclonal antibody | — | Intravenous |